Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa

INTRODUCTION: The rapid clearance of factor IX necessitates frequent intravenous administrations to achieve effective prophylaxis for patients with hemophilia B. Subcutaneous administration has historically been limited by low bioavailability and potency. Dalcinonacog alfa was developed using a rati...

Descripción completa

Detalles Bibliográficos
Autores principales: Nichols, Timothy C., Levy, Howard, Merricks, Elizabeth P., Raymer, Robin A., Lee, Martin L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592742/
https://www.ncbi.nlm.nih.gov/pubmed/33112889
http://dx.doi.org/10.1371/journal.pone.0240896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592742/
https://www.ncbi.nlm.nih.gov/pubmed/33112889
http://dx.doi.org/10.1371/journal.pone.0240896

Ejemplares similares